发明公开
EP1005870A3 Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
失效
嵌合的和标记的抗体的治疗用途其针对一个分化抗原，其表达仅限于人B淋巴细胞为B细胞淋巴瘤的治疗
- 专利标题： Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
- 专利标题（中）： 嵌合的和标记的抗体的治疗用途其针对一个分化抗原，其表达仅限于人B淋巴细胞为B细胞淋巴瘤的治疗
-
申请号： EP99123967.4申请日： 1993-11-12
-
公开(公告)号： EP1005870A3公开(公告)日： 2002-10-23
- 发明人: Anderson, Darrell R. , Hanna, Nabil , Leonard, John E. , Newman, Roland A. , Reff, Mitchell E. , Rastetter, William H.
- 申请人： IDEC PHARMACEUTICALS CORPORATION
- 申请人地址： 11011 Torreyana Road San Diego, CA 92121-1104 US
- 专利权人： IDEC PHARMACEUTICALS CORPORATION
- 当前专利权人： IDEC PHARMACEUTICALS CORPORATION
- 当前专利权人地址： 11011 Torreyana Road San Diego, CA 92121-1104 US
- 代理机构： Daniels, Jeffrey Nicholas
- 优先权： US978891 19921113; US149099 19931103
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; A61K51/10 ; C12N15/02 ; C12P21/08 ; C07K16/46
摘要：
Disclosed herein is an immunologically active, chimeric anti-CD20 antibody for use as a medicament, which antibody is capable of substantial B-cell depletion when administered to a subject.
公开/授权文献
信息查询
